BRIEF-Lavipharm Signs An Asset Purchase Agreement With Sanofi For The Acquisition Of Flagyl For The Greek Market Dec 11 (Reuters) - Lavipharm SA LPHr.AT : ENTERS INTO AN ASSET PURCHASE AGREEMENT WITH SANOFI FOR THE ACQUISITION OF THE PHARMACEUTICAL PRODUCT FLAGYL FOR THE GREEK MARKET COMMERCIALIZATION OF THE PRODUCT BY LAVIPHARM IS EXPECTED TO TAKE

BUZZ-India pharma sector growth slows in November on lower volumes ** India's pharmaceutical sector growth slowed to 2.9% year-on-year in November from 13.7% in October as volumes drop, data from All India Origin Chemists and Distributors (AIOCD) showed ** Volumes in November down 4.5% year-on-year after rising 5% in the previous month ** Dermatology and opthalmology segments witness fall in sales while anti-infectives, cardiac, respiratory segments see rise in sales in November ** Eris Lifescie

BRIEF-Innate Pharma: Efficacy And Safety Results Of NK Cell Engager SAR443579/IPH6101 Dec 11 (Reuters) - Innate Pharma SA IPH.PA : INNATE PHARMA SHARES EFFICACY AND SAFETY PHASE 1 /2 RESULTS OF NK CELL ENGAGER SAR443579 / IPH6101 DEVELOPED BY SANOFI AT ASH 2023 INNATE PHARMA SHARES EFFICACY AND SAFETY PHASE 1 /2 RESULTS OF NK CELL ENGAGER SAR443579

BRIEF-Sanofi Says Sarclisa Plus KRD Significantly Improved Rate Of Minimal Residual Disease Negativity In Transplant-Eligible Patients Dec 10 (Reuters) - Sanofi SA SASY.PA : SARCLISA (ISATUXIMAB) PLUS KRD SIGNIFICANTLY IMPROVED RATE OF MINIMAL RESIDUAL DISEASE NEGATIVITY IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA VERSUS K

BRIEF-Sanofi And Minapharm Sign An Exclusive Agreement For Localizing The Manufacture Of Clexane® Minapharm Pharmaceuticals SAE MIPH.CA : SANOFI AND MINAPHARM SIGN AN EXCLUSIVE AGREEMENT FOR LOCALIZING THE MANUFACTURE OF CLEXANE® Source text for Eikon: ID:nPreQDzYta Further company coverage: MIPH.CA